11 December 2024 in Clinical Chemistry and Laboratory Medicine (CCLM)
Objectives: An analytical protocol based on isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS), which includes a peptide-based calibration strategy, was developed and validated for the determination of cardiac troponin I (cTnI) levels in clinical samples. Additionally, the developed method was compared with a protein-based calibration strategy, using cTnI serving as a model for low-abundant proteins. The aim is to evaluate new approaches for protein quantification in complex matrices, supporting the metrology community in implementing new methods and developing fit-for-purpose SI- traceable peptide or protein primary calibrators. Methods: To establish traceability to SI units, peptide impurity correction amino acid analysis (PICAA) was conducted to determine the absolute content of signature peptides in the primary standards. Immunoaffinity enrichment was used to capture cTnI from human serum, with a comparison between microbeads and nanobeads to improve enrichment efficiency. Parallel reaction monitoring was used to monitor two signature peptides specific to cTnI. Various digestion parameters were optimized to achieve complete digestion. Results: The analytical method demonstrated selectivity and specificity, allowing the quantification of cTnI within 0.9–22.0 μg/L. The intermediate precision RSD was below 28.9 %, and the repeatability RSD was below 5.8 % at all concentration levels, with recovery rates ranging from 87 % to 121 %. The comparison of calibration strategies showed similar LOQ values, but the peptide-based calibration exhibited significant quantitative bias in recovery rates. The data are available via ProteomeXchange (PXD055104). Conclusions: This isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method, based on peptide calibration, successfully quantified cTnI in human serum. Comparing this with protein-based calibration highlighted both the strengths and potential limitations of peptide-based strategies.
21 September 2026 in Clinical Chemistry and Laboratory Medicine (CCLM)
The global harmonization of measurements in laboratory medicine is facilitated by the development and implementation of reference measurement systems, including suitable certified reference materials (CRMs). There are, however, a relatively small number of CRM producers worldwide. In the context of limited resources, strategic prioritization and coordinated action among CRM producers are critical. This position paper summarizes a Joint Committee for Traceability in Laboratory Medicine (JCTLM) workshop held in May 2026 that addressed the prioritization issue and relied on feedback from standardization leaders, experts in the field, and representatives of CRM producers. The workshop goals were to: a) determine whether ongoing activities can meet high-priority CRM development and maintenance needs; b) assess existing prioritization exercises and their level of consistency; and c) make recommendations on how to optimize processes for filling gaps in CRM availability, maintaining CRM supply, and avoiding unnecessary CRM redundancy. The identified stakeholder gaps and needs, the proposed solutions to address these needs, and an outline of a global coordination framework to optimize CRM coverage are discussed.
1 January 2024 in Metrologia
Main text: Under the auspices of the Protein Analysis Working Group (PAWG) of the Comité Consultatif pour la Quantité de Matière (CCQM) a pilot study, CCQM-P201, was organised. Five National Metrology Institutes (NMIs) participated in this pilot study and provided a total of eleven measurement results using six different methods based on three different measurement principles. The purpose of this pilot study was to develop measurement capabilities for the accurate quantification of intact haemoglobin (Hb) whereby measurement results could be made directly traceable to the SI. The choice of protein resulted from its ability to be quantified via different measurement principles providing different routes of traceability. Hb also provided a model of an intact protein with a complex tetrameric structure which is often measured via quantification of a specific subunit or the incorporated haem group. To achieve appropriate results for the chosen measurand, it was necessary to distinguish between the whole protein and fragments of the tetrameric structure, such as dimers or monomers. The participants were encouraged to investigate several of the measurement methods available. This was considered particularly advantageous in this instance as various methods applied to the same analyte may assist in identifying possible previously unknown biases or interferences of the various methods. Hb is being used as a model system to build capacity in methods for the quantification of proteins with a molar mass ≤ 100 kDa in biological fluids in a concentration range > 1∙106 pmol/g. This was the first pilot study for the quantification of an inherent protein in blood with all the natural variations that protein shows in a clinical sample. The different methods applied by the participants included isotopic dilution (ID) organic mass spectrometry (MS) of specific peptides after tryptic digestion, species-specific ID inductively coupled plasma mass spectrometry (ICP-MS), post-column ID ICP-MS, quantification via total iron after chromatographic isolation of Hb and acid digestion as well as two optical methods. One of the latter was the reference method proposed by the International Committee for Standardisation in Haematology (ICSH) based on the conversion of Hb to hemiglobincyanide (HiCN), the other used the conversion of Hb with alkaline haematin detergent both followed by the measurement of spectroscopic absorbance. Considering the use of very different measurement techniques for the quantification of total Hb, the results are in good agreement with a reference value with corresponding expanded uncertainty of (120.6 ± 1.2) mg/g calculated as DerSimonian-Laird mean. However, the observed differences between the results are not completely reflected in the reported measurement uncertainties. The calculated interlaboratory standard deviation or Tau value (dark uncertainty) was approximately 3 % whilst the average reported measurement uncertainty was approximately half this (1.4 %). A possible reason for this large difference may lie in the underestimation of any necessary conversion factors and their uncertainty contributions, between the target analyte measured and the requested measurand. To reach the main text of this paper, click on Final Report. Note that this text is that which appears in Appendix B of the BIPM key comparison database https://www.bipm.org/kcdb/. The final report has been peer-reviewed and approved for publication by the CCQM, according to the provisions of the CIPM Mutual Recognition Arrangement (CIPM MRA).